Daiichi, GSK India Units To Join In Promoting Japan Makers’ Drugs
This article was originally published in PharmAsia News
Daiichi Sankyo India Pharma and GlaxoSmithKline India plan a joint operation to promote the Japanese subsidiary's Benicar (olmesartan medoxomil) drug for treating hypertension. The deal for marketing Daiichi's $2 billion drug also includes promotion of the Japanese firm's combination products. Earlier, the U.K.-based GSK reached a similar agreement with Japan's Astellas to market its Mycamine (micafungin), all part of GSK's strategy of in-licensing products in high-growth therapeutic areas. The deal with GSK India also gives Daiichi an entry into the Indian market, which Daiichi Sankyo India plans to exploit. (Click here for more
You may also be interested in...
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.